Outcomes associated with warfarin use in older patients with heart failure and atrial fibrillation and a cardiovascular implantable electronic device: Findings from the ADHERE registry linked to medicare claims

Clinical Cardiology

Volumn 35, Issue 11, 2012, Pages 649-657

  Hess, Paul L ^a,b   Greiner, Melissa A ^a   Fonarow, Gregg C ^c   Klaskala, Winslow ^d   Mills, Roger M ^d   Setoguchi, Soko ^a,b   Al Khatib, Sana M ^a,b   Hernandez, Adrian F ^a,b   Curtis, Lesley H ^a,b  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UCLA MEDICAL CENTER   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WARFARIN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BILLING AND CLAIMS; BLEEDING; CARDIOVASCULAR EQUIPMENT; CAUSE OF DEATH; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; FEMALE; GERIATRIC PATIENT; HEART ATRIUM FIBRILLATION; HEART FAILURE; HOSPITAL DISCHARGE; HUMAN; HYPOTHESIS; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICARE; MORTALITY; PRESCRIPTION; THROMBOEMBOLISM; TREATMENT OUTCOME;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; CARDIAC PACING, ARTIFICIAL; CARDIAC RESYNCHRONIZATION THERAPY; CARDIAC RESYNCHRONIZATION THERAPY DEVICES; CHI-SQUARE DISTRIBUTION; DEFIBRILLATORS, IMPLANTABLE; ELECTRIC COUNTERSHOCK; FEMALE; HEART FAILURE; HEMORRHAGE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MEDICARE; MYOCARDIAL INFARCTION; PACEMAKER, ARTIFICIAL; PATIENT DISCHARGE; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; THROMBOEMBOLISM; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; WARFARIN;

EID: 84869501537     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22064     Document Type: Article

References (41)

1. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation. 1998; 98: 946-952. (Pubitemid 28446646)
2. Maisel W., Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol. 2003; 91: 2-8.
3. Olsson LG, Swedberg K, Ducharme A, et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: Results from the candesartan in heart failure-assessment of reduction in mortality and morbidity (charm) program. J Am Coll Cardiol. 2006; 47: 1997-2004.
4. Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation. Arch Intern Med. 1995; 155: 469-473.
5. Curtis LH, Whellan DJ, Hammill BG, et al. Incidence and prevalence of heart failure in elderly persons, 1994-2003. Arch Intern Med. 2008; 168: 418-424. (Pubitemid 351350587)
6. Goldberger Z, Lampert R., Implantable cardioverter-defibrillators: expanding indications and technologies. JAMA. 2006; 295: 809-818. (Pubitemid 43244308)
7. Hart RG, Pearce LA, Aguilar MI., Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146: 857-867. (Pubitemid 351650486)
8. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Arch Intern Med. 1994; 154: 1449-1457.
9. Birman-Deych E, Radford MJ, Nilasena DS, et al. Use and effectiveness of warfarin in medicare beneficiaries with atrial fibrillation. Stroke. 2006; 37: 1070-1074.
10. Smith P, Arnesen H, Holme I., The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med. 1990; 323: 147-152. (Pubitemid 20219942)
11. Hurlen M, Abdelnoor M, Smith P, et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002; 347: 969-974.
12. Hunt SA,; American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2005; 46: e1-e82.
13. Shah B, Hernandez AF, Liang L, et al. Hospital variation and characteristics of implantable cardioverter-defibrillator use in patients with heart failure: data from the GWTG-HF (Get With The Guidelines-Heart Failure) registry. J Am Coll Cardiol. 2009; 53: 416-422.
14. Fonarow GC, Albert NM, Curtis AB, et al. Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). Circulation. 2010; 122: 585-596.
15. Ogilvie IM, Newton N, Welner SA, et al. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010; 123: 638-645. e4.
16. Adams KF Jr, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005; 149: 209-216. (Pubitemid 40348525)
17. Kociol RD, Hammill BG, Fonarow GC, et al. Generalizability and longitudinal outcomes of a national heart failure clinical registry: comparison of Acute Decompensated Heart Failure National Registry (ADHERE) and non-ADHERE Medicare beneficiaries. Am Heart J. 2010; 160: 885-892.
18. Wahl PM, Rodgers K, Schneeweiss S, et al. Validation of claims-based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially-insured population. Pharmacoepidemiol Drug Saf. 2010; 19: 596-603.
19. Birman-Deych E, Waterman AD, Yan Y, et al. Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors. Med Care. 2005; 43: 480-485. (Pubitemid 40694609)
20. Rigler SK, Ellerbeck E, Whittle J, et al. Comparing methods to identify hip fracture in a nursing home population using Medicare claims. Osteoporos Int. 2011; 22: 57-61.
21. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: Results from the national registry of atrial fibrillation. JAMA. 2001; 285: 2864-2870. (Pubitemid 32537350)
22. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010; 137: 263-272.
23. Curtis LH, Hammill BG, Eisenstein EL, et al. Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases. Med Care. 2007; 45: S103-S107.
24. Krumholz HM, Parent EM, Tu N, et al. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Intern Med. 1997; 157: 99-104. (Pubitemid 27027080)
25. Austin PC, Grootendorst P, Anderson GM., A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med. 2007; 26: 734-753. (Pubitemid 46206593)
26. Leckey R, Aguilar EG, Phillips SJ., Atrial fibrillation and the use of warfarin in patients admitted to an acute stroke unit. Can J Cardiol. 2000; 16: 481-485. (Pubitemid 30245585)
27. Ageno W, Ambrosini F, Nardo B, et al. Atrial fibrillation and antithrombotic treatment in Italian hospitalized patients: a prospective, observational study. J Thromb Thrombolysis. 2001; 12: 225-230. (Pubitemid 34279443)
28. 2 score 0-1: a nationwide cohort study. Thromb Haemost. 2012; 107: 1172-1179.
29. 2 clinical prediction rule to predict ischaemic stroke. A systematic review and meta-analysis. Thromb Haemost. 2011; 106: 528-538.
30. Karthikeyan G, Eikelboom JW., The CHADS2 score for stroke risk stratification in atrial fibrillationâ€"friend or foe? Thromb Haemost. 2010; 104: 45-48.
31. Healey JS, Connolly SJ, Gold MR, et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012; 366: 120-129.
32. 2 score=1. Thromb Haemost. 2010; 103: 833-840.
33. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361: 1139-1151.
34. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365: 883-891.
35. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365: 981-992.
36. Ray WA., Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003; 158: 915-920. (Pubitemid 37323253)
37. Butler J, Arbogast PG, BeLue R, et al. Outpatient adherence to beta-blocker therapy after acute myocardial infarction. J Am Coll Cardiol. 2002; 40: 1589-1595. (Pubitemid 35253636)
38. Butler J, Arbogast PG, Daugherty J, et al. Outpatient utilization of angiotensin-converting enzyme inhibitors among heart failure patients after hospital discharge. J Am Coll Cardiol. 2004; 43: 2036-2043. (Pubitemid 38686798)
39. Fang MC, Go AS, Chang Y, et al. Warfarin discontinuation after starting warfarin for atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2010; 3: 624-631.
40. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery;, Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010; 31: 2369-2429.
41. Skanes AC, Healey JS, Cairns JA, et al. Canadian Cardiovascular Society Atrial Fibrillation Guidelines Committee. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol. 2012; 28: 125-136.